Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 322 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intradermal injection Clear all
Completed Phase 2 Interventional Results available

A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

NCT01309230
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Vigil™
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
7
States / cities
West Palm Beach, Florida • Lebanon, New Hampshire • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02439450
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Biological · Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
16
States / cities
Tucson, Arizona • La Jolla, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema

NCT05613946
View directory record Official record
Conditions
Lymphedema Arm
Interventions
Lumason, Optison, Definity
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

NCT02243371
View directory record Official record
Conditions
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Interventions
CRS-207, nivolumab, GVAX, CY
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Francisco, California • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Vascular Dysfunction in Hypertensive Postmenopausal Women

NCT03371823
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension
Interventions
Normotensive, Hypertensives
Other · Drug
Lead sponsor
University of Delaware
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects

NCT01324843
View directory record Official record
Conditions
Intradermal Electroporation
Interventions
EMLA Cream, Aveeno Daily Moist, Derma Vax, Intradermal Electroporation, Visual Analogue Scale, Present Pain Intensity, McGill Pain Questionnaire, Skin Assessment
Drug · Device · Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
View directory record Official record
Conditions
Microstomia, Scleroderma
Interventions
Hyaluronidase, CO2 laser
Drug · Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

NCT00601796
View directory record Official record
Conditions
Lung Cancer
Interventions
Vaccine Treatment, Cyclophosphamide, All-trans retinoic acid (ATRA)
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 15, 2026, 5:57 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

NCT04058197
View directory record Official record
Conditions
Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions
Deferoxamine Product, Placebo
Drug · Other
Lead sponsor
TauTona Group
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

NCT00847171
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Biological · Drug · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 15, 2026, 5:57 PM EDT
Withdrawn Not applicable Interventional

Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

NCT05106192
View directory record Official record
Conditions
Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma, Non Hodgkin Lymphoma, Lymphomatoid Papulosis, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Follicular
Interventions
Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel, Nitrogen Mustard, Conventional syringe
Device · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Multiple Antigen-Engineered DC Vaccine for Melanoma

NCT01622933
View directory record Official record
Conditions
Melanoma
Interventions
DC Vaccine + IFN, AdVTMM2/DC Vaccination
Biological
Lead sponsor
Lisa H. Butterfield, Ph.D.
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00112957
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
rV-NY-ESO-1 vaccine, rF-NY-ESO-1 vaccine
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PREVELLE Shape (CX002) Dermal Filler Protocol

NCT00764257
View directory record Official record
Conditions
Correction of Nasolabial Folds and Lip Augmentation
Interventions
PREVELLE Shape, Restylane
Device
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2011 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

NCT04435847
View directory record Official record
Conditions
Male Pattern Hair Loss
Interventions
HST 001, Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
25 Years to 55 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Sex Differences in the Dilatory Response of Compound 21

NCT05576155
View directory record Official record
Conditions
Sex Differences
Interventions
Compound 21, Compound 21 + losartan
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L/Montanide ISA 51 VG, Ampligen, Prevnar
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

NCT00013572
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer

NCT04411810
View directory record Official record
Conditions
Skin Cancer
Interventions
Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.

NCT01943110
View directory record Official record
Conditions
Injections, Intradermal
Interventions
ID adapter (autodisable), ID adapter (side load)
Device
Lead sponsor
PATH
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skin Surface and Intradermal Temperature Responses to Heat Stress

NCT06593067
View directory record Official record
Conditions
Hyperthermia
Interventions
Control, Fan, Fan and Water Spray, Water Spray
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 15, 2026, 5:57 PM EDT